United Theranostics Names a CFO for Its National Expansion
Private oncology network United Theranostics appointed Amber Woodward-Smith as finance chief and moved its prior CFO into development as it pursues outpatient expansion across the United States.
United Theranostics has appointed Amber Woodward-Smith as chief financial officer while moving former CFO Seth Van Voorhees into the chief development role. The changes align finance and expansion leadership as the private oncology company seeks to build an outpatient radiopharmaceutical therapy network across all 50 states.
Woodward-Smith brings more than two decades of healthcare finance, acquisition and operational experience. She previously held senior finance roles at Sarah Cannon Research Institute and worked on a joint venture involving HCA Healthcare and McKesson's US Oncology Research. Her appointment gives United Theranostics an executive familiar with integrating clinical organizations and negotiating transactions.
The company provides molecular imaging, treatment planning, radiopharmaceutical therapies, clinical research and patient support through outpatient centers. Its strategy is to move highly specialized cancer care beyond major academic hospitals and closer to community practices. That model could improve access, but scaling it requires capital, trained clinicians, radiation-safety infrastructure, isotope supply and reimbursement discipline.
The leadership transition is therefore more than a title change. Van Voorhees's move to development suggests that site expansion and partnerships will receive dedicated attention, while Woodward-Smith is expected to build the financial systems needed for a larger network.
Important commercial details remain undisclosed. United Theranostics did not provide the number of operating centers, a financing plan, expansion timetable, revenue, profitability or expected capital needs. Its goal of reaching physician practices in all 50 states is an ambition, not a completed footprint.
The company is privately held. The source's references to HCA Healthcare and McKesson describe Woodward-Smith's prior work and do not establish a direct financial impact on either listed company. HCA was incorrectly attached as the source ticker and has been removed from the editorial mapping.
For investors following the radiopharmaceutical sector, United Theranostics illustrates the infrastructure challenge behind new therapies. Drug approvals alone do not create access; diagnostic imaging, handling capability and local treatment capacity must expand as well. The appointment supports that buildout, but evidence of value will come from funded sites, patient volumes, payer coverage and sustainable center economics rather than the executive announcement by itself.